DDCB coordinates infrastructure and expertise in the areas of drug discovery and chemical biology and makes it available to the scientific community. The DDCB platform provides services in assay development and chemical screening from medium to high throughput with a broad range of technologies including the DDCB-developed drug sensitivity and resistance testing platform. Our service portfolio also includes antibacterial screening, specialized assays for novel materials, repurposing of drugs, virtual screening, chemoinformatics, as well as open access to a large national chemical collection, translational support and user base education.
Contact details
Platform Chair
Päivi Tammela
paivi.tammela@helsinki.fi
Nodes
UEF: University of Eastern Finland; UH: University of Helsinki; UTU: University of Turku
Services
- Project and assay guidance and development support – all sites
- Chemical screening – FIMM and Faculty of Pharmacy, UH, BioCity Turku
- Drug sensitivity and resistance screening (DSRT) and drug repurposing – FIMM
- Chemoinformatics, molecular modeling, and virtual screening – Biocenter Kuopio, Faculty of Pharmacy, UH, and BioCity Turku
- Follow-up screening and testing – all sites
- Access to a large national chemical collection – FIMM
Recent user publications
Pietiäinen V, Polso M, Migh E, Guckelsberger C, Harmati M, Diosdi A, Turunen L, Hassinen A, Potdar S, Koponen A, Sebestyen EG, Kovacs F, Kriston A, Hollandi R, Burian K, Terhes G, Visnyovszki A, Fodor E, Lacza Z, Kantele A, Kolehmainen P, Kakkola L, Strandin T, Levanov L, Kallioniemi O, Kemeny L, Julkunen I, Vapalahti O, Buzas K, Paavolainen L, Horvath P, Hepojoki J. Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2. Cell Rep Methods. 2023, 3, 100565. doi: 10.1016/j.crmeth.2023.100565.
Jokinen EM, Niemeläinen M, Kurkinen ST, Lehtonen JV, Lätti S, Postila PA, Pentikäinen OT, Niinivehmas S. Virtual Screening Strategy to Identify Retinoic Acid-Related Orphan Receptor γt Modulators. Molecules. 2023, 28, 3420. doi: 10.3390/molecules28083420
Asquith CRM, Temme L, East MP, Laitinen T, Pickett J, Kwarcinski FE, Sinha P, Wells CI, Johnson GL, Zutshi R, Drewry DH. Identification of 4-Anilinoquin(az)oline as a Cell-Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype. ChemMedChem. 2022, e202200161. doi: 10.1002/cmdc.202200161
Malani D, Kumar A, Bruck O, Kontro M, Yadav B, Hellesoy M, Kuusanmaki H, Dufva O, Kankainen M, Eldfors S, Potdar S, Saarela J, Turunen L, Parsons A, Vastrik I, Kivinen K, Saarela J, Raty R, Lehto M, Wolf M, Gjertsen BT, Mustjoki S, Aittokallio T, Wennerberg K, Heckman CA, Kallioniemi O, Porkka K. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discovery. 2022; 12, 1-14. doi: 10.1158/2159-8290.CD-21-0410.
Mäki-Mikola E, Lauren P, Uema N, Kikuchi K, Takashima Y, Laaksonen T, Lajunen T. Establishing a simple perfusion cell culture system for light-activated liposomes. Sci Rep. 2023, 13, 2050. doi: 10.1038/s41598-023-29215-6
